COST EFFECTIVENESS OF ONASEMNOGENE ABEPARVOVEC IN INFANTS WITH PRESYMPTOMATIC SPINAL MUSCULAR ATROPHY IN ITALY

被引：0
|
作者：
Valentini, I [1 ,2 ]
Ghetti, G. [3 ]
Pane, M. [4 ]
Cicchetti, A. [1 ,2 ]
Rumi, F. [5 ]
Di Brino, E. [1 ,2 ]
Basile, M. [5 ]
Pistillo, G. [6 ]
Bischof, M. [7 ]
机构：
[1] Cattolica Sacro Cuore Univ UCSC, Fac Econ, Rome, Italy
[2] Cattolica Sacro Cuore Univ, Grad Sch Hlth Econ & Management ALTEMS, Rome, Italy
[3] AdRes HEOR, Turin, To, Italy
[4] Fdn Policlin Univ Agostino Gemelli, Rome, Italy
[5] Univ Cattolica Sacro Cuore, Grad Sch Hlth Econ & Management ALTEMS, Rome, Italy
[6] Novartis Gene Therapies, Legnano, MI, Italy
[7] Novartis Gene Therapies GmbH, Rotkreuz, Switzerland
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
RWD129
引用
收藏
页码：S528 / S529
页数：2
相关论文
共 50 条
  • [31] Onasemnogene abeparvovec gene-replacement therapy (GRT) in presymptomatic spinal muscular atrophy (SMA): SPR1NT study update
    Strauss, K. A.
    Swoboda, K. J.
    Farrar, M. A.
    McMillan, H. J.
    Parsons, J.
    Krueger, J. M.
    Iannaccone, S. T.
    Chiriboga, C. A.
    Kwon, J. M.
    Saito, K.
    Scoto, M.
    Baldinetti, F.
    Schultz, M.
    Kernbauer, E.
    Farrow, M.
    Ogrinc, F. G.
    Kavanagh, S.
    Feltner, D. E.
    McGill, B. E.
    Spector, S. A.
    L'Italien, J.
    Sproule, D. M.
    Muntoni, F.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2019, 405
  • [32] COST-EFFECTIVENESS AND BUDGET IMPACT OF ONASEMNOGENE ABEPARVOVEC FOR SPINAL MUSCULAR ATROPHY TYPE 1: POST-HOC ANALYSIS OF A MODEL DEVELOPED BY ICER
    Dabbous, O.
    Dean, R.
    Arjunji, R.
    Sproule, D. M.
    Feltner, D. E.
    Malone, D. C.
    VALUE IN HEALTH, 2019, 22 : S850 - S850
  • [33] Meta-analysis of clinical impact of onasemnogene abeparvovec treatment of spinal muscular atrophy patients
    Reyna, S.
    Dabbous, O.
    Wallach, S.
    Patel, A.
    Toro, W.
    Ritter, S.
    NEUROMUSCULAR DISORDERS, 2024, 43
  • [34] Treatment of spinal muscular atrophy with Onasemnogene Abeparvovec in Switzerland: a prospective observational case series study
    Georg M. Stettner
    Oswald Hasselmann
    Anne Tscherter
    Elea Galiart
    David Jacquier
    Andrea Klein
    BMC Neurology, 23
  • [35] Intravenous and Intrathecal Onasemnogene Abeparvovec Gene Therapy in Symptomatic and Presymptomatic Spinal Muscular Atrophy: Long-Term Follow-Up Study
    Darras, Basil
    Mercuri, Eugenio
    Strauss, Kevin
    Day, John
    Chien, Yin-Hsiu
    Masson, Ricardo
    Wigderson, Melissa
    Alecu, Iulian
    Ballarini, Nicolas
    Mehl, Lesa
    Marra, Jonathan
    Connolly, Anne
    NEUROLOGY, 2023, 100 (17)
  • [36] Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial
    Strauss, Kevin A.
    Farrar, Michelle A.
    Muntoni, Francesco
    Saito, Kayoko
    Mendell, Jerry R.
    Servais, Laurent
    McMillan, Hugh J.
    Finkel, Richard S.
    Swoboda, Kathryn J.
    Kwon, Jennifer M.
    Zaidman, Craig M.
    Chiriboga, Claudia A.
    Iannaccone, Susan T.
    Krueger, Jena M.
    Parsons, Julie A.
    Shieh, Perry B.
    Kavanagh, Sarah
    Tauscher-Wisniewski, Sitra
    McGill, Bryan E.
    Macek, Thomas A.
    NATURE MEDICINE, 2022, 28 (07) : 1381 - +
  • [37] Early Cost-Effectiveness of Onasemnogene Abeparvovec-xioi (Zolgensma) and Nusinersen (Spinraza) Treatment for Spinal Muscular Atrophy I in The Netherlands With Relapse Scenarios
    Broekhoff, Thomas F.
    Sweegers, Carly C. G.
    Krijkamp, Eline M.
    Mantel-Teeuwisse, Aukje K.
    Leufkens, Hubert G. M.
    Goettsch, Wim G.
    Vreman, Rick A.
    VALUE IN HEALTH, 2021, 24 (06) : 759 - 769
  • [38] Onasemnogene Abeparvovec in Type 1 Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis
    Pascual-Morena, Carlos
    Cavero-Redondo, Ivan
    Luceron-Lucas-Torres, Maribel
    Martinez-Garcia, Irene
    Rodriguez-Gutierrez, Eva
    Martinez-Vizcaino, Vicente
    HUMAN GENE THERAPY, 2023, 34 (3-4) : 129 - 138
  • [39] Onasemnogene abeparvovec in spinal muscular atrophy : predictors of efficacy and safety in naive patients with spinal muscular atrophy and following switch from other therapies
    Pane, Marika
    Berti, Beatrice
    Capasso, Anna
    Coratti, Giorgia
    Varone, Antonio
    D'Amico, Adele
    Messina, Sonia
    Masson, Riccardo
    Sansone, Valeria Ada
    Donati, Maria Alice
    Agosto, Caterina
    Bruno, Claudio
    Ricci, Federica
    Pini, Antonella
    Gagliardi, Delio
    Filosto, Massimiliano
    Corti, Stefania
    Leone, Daniela
    Palermo, Concetta
    Onesimo, Roberta
    De Sanctis, Roberto
    Ricci, Martina
    Bitetti, Ilaria
    Sframeli, Maria
    Dosi, Claudia
    Albamonte, Emilio
    Ticci, Chiara
    Brolatti, Noemi
    Bertini, Enrico
    Finkel, Richard
    Mercuri, Eugenio
    ECLINICALMEDICINE, 2023, 59
  • [40] Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy
    Chand, Deepa
    Mohr, Franziska
    McMillan, Hugh
    Tukov, Francis Fonyuy
    Montgomery, Kyle
    Kleyn, Aaron
    Sun, Rui
    Tauscher-Wisniewski, Sitra
    Kaufmann, Petra
    Kullak-Ublick, Gerd
    JOURNAL OF HEPATOLOGY, 2021, 74 (03) : 560 - 566
12345